重组应用重组不刺激红细胞生成素受体阳性乳腺癌肿瘤生长模型。
文章的细节
-
引用
复制到剪贴板 -
LaMontagne KR,巴特勒J,马歇尔DJ, Tullai J, Gechtman Z,大厅C, Meshaw,法雷尔外汇
重组应用重组不刺激红细胞生成素受体阳性乳腺癌肿瘤生长模型。
摩尔癌症。”2006年2月,5 (2):347 - 55。
- PubMed ID
-
16505108 (在PubMed]
- 文摘
-
我们调查的意义治疗后红细胞生成素受体(EPOR)表达重组人红细胞生成素(rHuEPO;重组α)和重组的影响重组(重组α,重组β和αdarbepoetin)单独或结合抗癌疗法在肿瘤生长两种乳腺癌的临床前模型(mda - mb - 231和MCF-7细胞株)。表达和本地化EPOR缺氧和常氧条件下mda - mb - 231和MCF-7细胞被免疫印迹评估,流式细胞术和免疫组织化学。EPOR绑定使用[125 i] rHuEPO评估。增殖、迁移和信号在mda - mb - 231和MCF-7细胞治疗rHuEPO进行评估。肿瘤生长评估管理重组后单独应用重组,结合紫杉醇(抗癌疗法)orthotopically植入mda - mb - 231和MCF-7乳腺癌异种移植模型在无胸腺的老鼠。EPOR表达肿瘤细胞系中检测到。EPOR定位被发现只胞质,没有特定的观察[125 i] rHuEPO绑定。没有刺激迁移、扩散或激活增殖蛋白激酶和AKT rHuEPO治疗。在老鼠中,重组单独应用重组,结合紫杉醇治疗导致等效肿瘤负担而vehicle-treated控制。 Results from our study suggest that although EPOR expression was observed in two well-established breast carcinoma cell lines, it was localized to a cytosolic distribution and did not transduce a signaling cascade in tumors that leads to tumor growth. The addition of recombinant epoetins to paclitaxel did not affect the outcome of paclitaxel therapy in breast carcinoma xenograft models. These results show that recombinant epoetins do not evoke a physiologic response on EPOR-bearing tumor cells as assessed by numerous variables, including growth, migration, and cytotoxic challenge in preclinical in vivo tumor models.